Respiratory

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP), shares updates on the Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025, which was introduced in the House of Representatives last month.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

The value of the combination of albuterol/budesonide is high due to its alleviating of corticosteroid burden, according to Reynold Panettieri Jr, MD.

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN trial.

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

Respiratory diseases made up the hospitalizations in older adults after they were exposed to wildfire smoke.

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

Edgardo S. Santos, MD, FACP, FASCO, a hematologist and medical oncologist, discussed how artificial intelligence (AI) is revolutionizing lung cancer care by analyzing imaging data to detect malignancies and interstitial lung disease, while stressing the importance of regulation to ensure its safe and ethical use.

Inhaling wildfire smoke could have immediate effects on children in Los Angeles, such as coughing and wheezing, which may lead to more long-term health effects.

Both candidates combine 2 already licensed vaccines to prevent influenza and COVID-19.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory syncytial virus (RSV).

A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on vaccines for flu and respiratory syncytial virus (RSV).

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).

The COVID-19 pandemic required an evolution of traditional nursing practices, but the unpredictability led to increased stress, burnout, and job dissatisfaction.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).

Introducing artificial intelligence (AI)–powered robots like AMECA into health care comes with potential benefits like improved clinical decision-making and faster diagnoses, but also presents challenges such as misinformation risks and data privacy concerns.

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.